Tango Biosciences

Tango Biosciences develops highly sensitive and specific custom recombinant affinity reagents using advanced phage display technologies. Their solutions have enabled the rapid generation of peptide ligands, monobodies, and antibody-like proteins against diverse targets including viral proteins and disease biomarkers. The company has published work on SARS-CoV‑2 RBD binders and received NIH grants to develop reagents for infectious diseases and oncology/cardiology biomarker detection. They are recognized as a leading CRO in this niche with a track record of enabling both academic and industry partners in assay development, drug screening, diagnostics, and therapeutic discovery. No direct clinical results as they are not developing therapeutics themselves but enable such programs through their services. Recognized as one of the top bioscience start-ups in recent years.